Revenue
2020
2021
2022
2023
2024
2025
Healthcare Triangle, Inc. (HCTI)
Price$0.79075Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $13.9M | $11.7M | $33.2M | $45.9M | $35.3M | $31.3M |
| Gross profit | $1.24B | $1.07B | $1.07B | $11.3M | $10.5M | $8.6M |
| Gross margin | 8,890.65% | 9,148.43% | 3,222.60% | 24.62% | 29.83% | 27.40% |
| Research & development | $536,000 | $429,000 | $799,000 | $8.1M | $5.3M | $1.7M |
| Operating expenses | $11.7M | $7.6M | $14.5M | $27.6M | $15.9M | $7.4M |
| Operating income | −$9.8M | −$4.8M | −$7.7M | −$16.3M | −$5.4M | $1.2M |
| Operating margin | −70.47% | −40.62% | −23.18% | −35.57% | −15.19% | 3.75% |
| EBITDA | −$9.1M | −$3.9M | −$6.1M | −$13.4M | −$3.9M | $2.0M |
| EBITDA margin | −65.39% | −33.02% | −18.46% | −29.16% | −11.16% | 6.32% |
| Net income | −$9.5M | −$6.0M | −$8.7M | −$14.4M | −$5.9M | $2.4M |
| Net profit margin | −68.22% | −51.03% | −26.16% | −31.29% | −16.87% | 7.51% |
| Basic EPSper basic share | -$152.30 | -$16,909.30 | -$124.80 | -$232.80 | -$121.20 | $50.40 |
| Diluted EPSper diluted share | -$152.30 | -$16,909.30 | -$124.80 | -$232.80 | -$121.20 | $50.40 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Kannappan Lakshmanan | 324.18K |
Kizhakevilayil Shibu | 54.13K |
Ramachandran Thyagarajan | 29.63K |
BANK OF MONTREAL /CAN/ | 20K |
GEODE CAPITAL MANAGEMENT, LLC | 11.98K |
UBS Group AG | 8.86K |
Tower Research Capital LLC (TRC) | 1.31K |
VANGUARD CAPITAL MANAGEMENT LLC | 859 |
BARCLAYS PLC | 310 |
JPMORGAN CHASE & CO | 20 |
DANSKE BANK A/S | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data